NYSE:JNJPharmaceuticals
Should J&J’s Lupus Drug and Surgical Robotics Advances Require Action From Johnson & Johnson (JNJ) Investors?
In early January 2026, Johnson & Johnson reported encouraging Phase 2b results for its lupus drug nipocalimab and submitted its OTTAVA robotic surgical system to the FDA for De Novo classification, supported by IDE clinical trial data in multiple upper-abdominal general surgery procedures and a newly approved U.S. trial in inguinal hernia repair.
Together, these advances highlight Johnson & Johnson’s push to pair an expanding autoimmune drug pipeline with next-generation surgical robotics,...